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Abstract: The aim of the present work was the optimization of the 
transdermal delivery of a lyotropic liquid crystal genistein-based 
formulation (LLC-GEN). LLC was chosen as medium in view of the poor 
solubility of GEN in water. Membrane diffusion and penetration studies 
were carried out with a Franz diffusion cell, through a synthetic membrane 
in vitro, a chick chorioallantoic membrane ex ovo, and ex vivo excised 
human epidermis. Thereafter, LLC-GEN was combined with 
electroporation (EP) to enhance the transdermal drug delivery. The 
synergistic effect of EP was verified by in vivo ATR-FTIR and ex vivo 
Raman spectroscopy on hairless mouse skin. 
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1. Introduction 
The transport of molecules through the skin is made difficult by the presence of the stratum 
corneum (SC). The epidermis is an intricate and highly inhomogeneous structure built up 
from different layers, but the SC (the outermost layer of the skin consisting of dead flattened 
cells) causes its barrier function, such as the electrical properties [1, 2]. Transdermal drug 
delivery has a number of advantages over conventional delivery methods such as oral 
administration and injection (e.g. elimination of the first-pass metabolism, the minimization 
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of pain, and the possibility of the sustained release of drugs). However, for the delivery of 
large molecules through the skin, the use of chemical or physical methods is unavoidable [1]. 
Electroporation (EP) involves the application of short (microsecond to millisecond) pulses 
of high voltage (HV) to achieve a transitory structural perturbation of the lipid bilayer 
membranes. Its main advantages are that it is easy and rapid, and is able to open different 
kinds of lipid bilayer membranes: artificial (liposomes), cellular (bacterial, yeast, plant and 
mammalian cells) or even more complex structures (e.g. SC) [3]. Through the use of skin EP, 
the transdermal delivery of small dyes, drugs, oligonucleotides, DNA plasmids, antigens, 
hydrophilic molecules, neutral or highly charged compounds, and macromolecules with 
molecular weights up to 40 kDa can be enhanced by several orders of magnitude [4, 5]. 
Currently the most broadly developing area of EP is electrochemotherapy, which is an 
effective way to treat cutaneous and subcutaneous tumours: HV pulses are applied to 
permeabilize tumour cells to an impermeable cytotoxic drug, which is administered by 
injection either into a vein or directly into a tumour [6]. 
Genistein (GEN; 4,5,7-trihydroxyisoflavone), one of the most abundant isoflavones in 
soybeans, is also called a phytoestrogen because of its structural similarity to the human 
hormone 17β-oestradiol [7]. GEN, a potent tyrosine kinase inhibitor, has been extensively 
used in the prevention and treatment of many diseases and disorders, including cancer, 
cardiovascular diseases, osteoporosis and postmenopausal symptoms [8]. Danciu et al. 
demonstrated the beneficial effects of GEN as regards tumour size, metastasis potential and 
melanization in a B16 mouse model of murine melanoma [9]. However, GEN is only poorly 
soluble in water and this can be a serious problem in terms of formulation [10]. 
A topically applied GEN-based lyotropic liquid crystal (LLC) formulation was earlier 
developed and combined with EP to treat murine melanoma lesions [11, 12]. The results 
showed that this strategy is promising for the recovery of skin lesions of murine melanoma 
type. LLCs are novel nanosystems usually formed from water and one or two surfactants, 
possibly with cosurfactants and oils. The main advantages of these systems include their 
similarity with colloidal systems existing in living organisms, their thermodynamic stability, 
and the situations that they can be stored for long periods of time without phase separation, 
they exhibit good penetration and they can facilitate the progressive diffusion of biologically 
active substances into the skin or systemic circulation. Besides their good solubilizing effects, 
they are able to incorporate and control the release of drugs of varying size and polar 
characteristics as they contain lipophilic, hydrophilic and amphiphilic domains [13, 14]. 
In the present work, the diffusion and penetration of GEN and LLC-GEN through 
different membranes were first investigated by conventional treatment without EP, and also 
with the mediation of EP. Measurements were made with a Franz diffusion cell system 
through a synthetic membrane in vitro, chick chorioallantoic membrane (CAM) ex ovo and 
excised human epidermis ex vivo. CAM has been introduced as a new and useful biological 
membrane model for preclinical permeability studies of pharmaceutical substances [15]. 
Vibrational spectroscopies were used to investigate the effects of EP on animal skin. 
Infrared (IR) and Raman spectroscopy have recently received increased attention in both the 
cosmetic and pharmaceutical fields. These methods offer attractive possibilities for the study 
of EP-mediated drug delivery. 
Attenuated total reflection Fourier transform IR spectroscopy (ATR-FTIR) is a suitable 
tool with which to study the structure of the SC at the molecular level, to characterize its 
lipids, proteins and water content [16], and to analyse the penetration of drugs into the skin 
and the biochemical modifications induced by the penetration [17]. ATR-FTIR is essentially a 
non-destructive sampling technique which combined with tape-stripping serves as a rapid, 
simple, non-invasive method for studies of the skin. Through sequential tape-stripping, SC 
layers can be obtained from the deeper regions. The ATR device allows a spectrum to be 
acquired from a surface of a sample without preparation [18]. FTIR spectrometric studies on 
GEN have been investigated and reported earlier [19]. 
Raman spectroscopy is also widely used to study biological samples and to study the skin 
[20]. It has been utilized to determine the structures of GEN-cyclodextrin inclusion complexes 
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[21], GEN and other 5-hydroxyisoflavones [22]. The assignment of the Raman spectrum of 
native skin was reported by Pouliot [23]. Confocal Raman images have been investigated as 
chemical maps of ex vivo pigskin [24] and ex vivo human abdominal skin [25]. 
Following an investigation of the transdermal delivery of our newly developed LLC-GEN 
formulation through different membranes without EP, LLC-GEN was combined with EP to 
examine the efficiency of this combination by means of in vivo ATR-FTIR and ex vivo Raman 
spectroscopy. With vibrational spectroscopic monitoring, various treatment times and 
voltages were applied to evaluate the effects of EP on the skin. 
2. Materials and methods 
2.1. Materials 
GEN was purchased from Extrasynthèse (Genay, France; purity >95%), and the non-ionic 
surfactant Cremophor RH 40 (CRH40; Polyoxyl 40 Hydrogenated Castor Oil USP/NF) from 
BASF (Ludwigshafen, Germany). The aqueous phase of the systems was purified water 
(Ph.Eur.6.), and the oil phase was isopropyl myristate (IPM; Merck Kft., Budapest, Hungary). 
The average particle size of GEN is 12.04 ± 7.74 µm (n = 564). 
2.2. Sample preparation 
Samples produced with a 2:1 by the oil-surfactant mixture were homogenized with a magnetic 
stirrer at room temperature, and 10 wt.% of water was then added in small amounts under 
stirring. For the drug-containing samples, 3 wt.% of GEN as active agent was partly dissolved 
(1 wt.%) in the oil-surfactant mixture with the aid of a magnetic stirrer. 
2.3. Drug diffusion and penetration investigations 
2.3.1. Preparation of CAM 
Fertilized chicken eggs (Gallus gallus domesticus) were prepared for the experiment by 
cleaning with ethanol, and then placed horizontally in an incubator at 37 °C, with constant 
humidity. On the third day of incubation, 3–4 mL of albumen was extracted from the most 
pointed part of the egg, so that the developing CAM could be detached from the inner shell in 
order to work directly on the membrane. On day 4 of incubation, a window was cut in the 
surface of the egg, it was resealed with adhesive tape and incubation was continued until the 
day of the experiment. CAMs were collected in buffered formalin and used for ex ovo studies. 
2.3.2. Preparation of heat-separated epidermis 
With the approval of the Ethical Committee of the University of Szeged, Albert Szent-
Györgyi Clinical Centre (Human Investigation Review Board licence number: 83/2008.), 
excised human skin was obtained from a Caucasian female patient who underwent abdominal 
plastic surgery. This was. The subcutaneous fatty tissue was separated from the outer skin 
layers after excision and the skin was stored at −20 °C. For the penetration experiment, after 
the skin had thawed, the epidermis was separated from the underlying dermis by a heat-
separation technique [26]. Individual portions were immersed in water at 60 °C for 90 s. After 
removal of the skin from the water, it was placed SC side up on a filter paper, and the 
epidermis (comprising the SC and the viable epidermis) was gently removed from the 
underlying dermis with the use of forceps and was discarded. The epidermal membrane was 
floated onto the surface of PBS (phosphate buffer solution, pH = 7.4) for at least 20 min and 
then placed on a supporting cellulose acetate membrane (Porafil, Machenerey-Nagel, Düren, 
Germany, and Pall Life Sciences, Washington, NY, USA; pore diameter 0.45 μm) [27, 28]. 
2.3.3. Franz diffusion cell method 
Membrane diffusion and permeability studies of GEN were carried out with a vertical Franz 
diffusion cell system (Hanson Research, Chatsworth, CA, USA) in a six-unit assembly 
(effective permeation area 1.33 cm2) for 24 h (in vitro or ex ovo) or 48 h (human epidermis) at 
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37 °C. The donor phase was 0.30 g of sample, which was placed on a cellulose acetate 
membrane (Porafil, Machenerey-Nagel, Düren, Germany, and Pall Life Sciences, 
Washington, NY, USA) itself (in vitro), or in the case of ex ovo and ex vivo measurements the 
CAM and the epidermis were supported with a Porafil membrane filter. The acceptor 
compartment consisted of 10 wt.% ethanol containing PBS (pH 7.4), which was stirred at 450 
rpm throughout the experiment. Samples of 0.8 mL were taken from the acceptor phase by the 
autosampler (Hanson Research, Chatsworth, CA, USA) and replaced with an equal volume of 
fresh receiving medium. The absorbance of the GEN content was measured at 261 nm with a 
Unicam Heλios α Thermospectronic UV-spectrophotometer v4.55 (Unicam, Thermo Fisher 
Scientific Inc., Waltham, MA, USA). Five parallel measurements were carried out and the 
amount of GEN penetrating during a time period was plotted. The results were expressed as 
means ± SEM. 
2.3.4. Penetration analysis 
Penetration parameters were obtained from the cumulative amount of GEN penetrated per 
cm2 versus time plots (Q). The transdermal flux (J) was calculated from the slope of the 
concentration versus time profile in the receiver compartment, and expressed in µg cm−2 h−1. 
For the linear regression analysis, the linear range of the incubation period from 1 to 6 h was 
selected, and was used to calculate the flux data of the compounds. 
2.4. EP parameters 
A Mezoforte Duo Mez 120905-D instrument (Dr Derm Equipment Ltd., Budapest, Hungary) 
was used to generate the electric pulses for the skin EP. The operation of this device is based 
on a pulsed electromagnetic field generated by an amplitude-modulated sine wave 
radiofrequency current. The polypropylene-covered treatment headpiece contains a plate 
electrode 25 mm in diameter indirectly contact with the treated surface. Modulation involves 
HV pulses 5 ms in duration, followed by a 20 ms break. GEN transport by means of skin EP 
can be influenced by using 700 V or 900 V with different treatment times (1 or 2 min). 
2.5. Animal experiments 
12-week-old male SKH-1 hairless mice were housed in plastic cages in a thermoneutral 
environment with a 12 h light-dark cycle and had access to standard laboratory chow and 
water ad libitum. All interventions were in full accordance with the NIH guidelines and the 
protocols were approved in advance by the Ethical Committee for the Protection of Animals 
in Scientific Research at the University of Szeged (licence number: V./145/2013). Prior to the 
intervention, the animals were anaesthetized with a mixture of ketamine (90 mg (kg 
bodyweight)−1) and xylazine (25 mg (kg bodyweight)−1) administered intraperitoneally. At the 
end of the experiments, the mice were euthanized with an overdose of ketamine (300 mg 
kg−1). 
The mice involved in the study were divided into 5 groups as follows: 
Group A: mice treated with dermally applied LLC-GEN for 2 min 
(conventional treatment) 
Group B: mice treated with LLC-GEN and EP at 700 V for 1 min 
Group C: mice treated with LLC-GEN and EP at 900 V for 1 min 
Group D: mice treated with LLC-GEN and EP at 700 V for 2 min 
Group E: mice treated with LLC-GEN and EP at 900 V for 2 min 
For ATR-FTIR measurements, 5 mice were randomly assigned to each experimental 
condition. Corneocytes were collected from the uppermost layer of their dorsal skin with the 
use of adhesive tape (D Squames, CuDerm Corporation, Dallas, TX, USA) immediately after 
treatment. The treated and the untreated dorsal skin of each mouse was stripped with adhesive 
tape; this procedure was repeated up to 18 strips, an IR spectrum being recorded after every 
third tape strip. Every first tape with one strip was discarded because of the possibility of 
surface contamination. 
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For Raman measurements, 2 mice were randomly assigned to each of groups A, C and E. 
At the end of the observation period of these groups, the animals were sacrificed (as described 
above) and full-thickness skin samples were excised from the treated areas. The samples were 
embedded in Cryomatrix resin (Thermo Fisher Scientific Inc., Waltham, MA, USA) and 
cryosections of 6 μm were made. 
2.6. ATR-FTIR measurements 
ATR-FTIR spectra were recorded with an Avatar 330 FT-IR spectrometer (Thermo Fisher 
Scientific Inc., Waltham, MA, USA) equipped with a horizontal ATR crystal (ZnSe, 45°), 
between 4000 and 400 cm−1, at an optical resolution of 4 cm−1. 128 scans were co-added and 
all spectral manipulations were performed with the Thermo Scientific's GRAMS/AI Suite 
software. In order to obtain a reference spectrum of the API, a KBr pellet containing 0.5 mg 
of GEN was prepared and used. The spectra of the preparations were also recorded. The 
spectra of five parallel samples, gained from five different animals, were recorded. Each 
average layer spectrum of the treated SC was corrected with the corresponding average layer 
spectrum of the untreated SC. No ATR correction was performed. 
2.7. Raman measurements 
Raman spectra were acquired with a Dispersive Raman Microscope (Thermo Fisher Scientific 
Inc., Waltham, MA, USA) equipped with a CCD camera and a diode laser operating at 780 
nm. The spectra of the CRH40, IPM and GEN were collected with an exposure time of 6 s, 
with 48 scanning and cosmic ray and fluorescence corrections. Raman measurements were 
carried out with a laser power of 12 mW at a slit width of 25 µm. The localization of GEN in 
the skin samples was investigated by confocal Raman mapping. For mapping, the microtomed 
skin samples as depth sections were rotated by 90° and placed on an aluminium surface with 
the SC towards the top of the plate. Thus, a 1000 µm length of the sample specimen 
corresponds to a 1000 µm depth into the skin. The mapping was achieved in a point-by-point 
mode, using a step size of 10 µm perpendicular and parallel to the SC. Raman maps of skin 
with dimensions 30-40 µm parallel and 900-1300 µm perpendicular to the SC surface were 
generated one-by-one. The spectrum acquisition time was 3 s per spectrum, and 24 spectra 
were accumulated and averaged at each measured point, these parameters ensuring an 
acceptable signal-to-noise ratio. The mapping was carried out with a laser power of 24 mW at 
a slit width of 25 µm. The vibrational chemical images were studied by a multivariate curve 
resolution – alternating least squares chemometric method; the purpose was to identify GEN 
in the Raman spectra. 
2.8. Statistical analysis 
Two-way ANOVA was used to identify any significant differences in the total penetrated 
amount of GEN between the conventional treatment and the combined EP treatments by using 
GraphPad Prism software (Graph-Pad Software Inc., La Jolla, CA, USA). Differences were 
regarded as significant if p < 0.05* and p < 0.001***. 
3. Results and discussion 
3.1. Drug diffusion and penetration 
The membrane diffusion investigations indicated that good drug release and diffusion was 
attained through the synthetic membrane in vitro, 713.26 ± 90.73 µg cm−2 being liberated in 
24 h (Fig. 1(a)). Somewhat less drug was observed after 24 h (491.26 ± 15.55 µg cm−2) in the 
case of ex ovo penetration (Fig. 1(b)). In the ex vivo investigations which revealed not only 
the amount of drug that diffused through the skin, but also the interaction with the skin and 
the incidental reservoir function of the SC, only a small amount of drug penetrated through 
the human epidermis (8.93 ± 1.81 µg cm−2 after 24 h and 15.68 ± 3.09 µg cm−2 after 48 h), but 
the penetration profile was similar to that for ex ovo penetration and sustained drug release 
was achieved (Fig. 1(c)). The transdermal flux (J) (reflecting the absorption rate per unit area) 
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showed that the drug penetration was slowed down by the application of the biological 
membrane, and that LLC-GEN alone was not sufficient to reach an appropriate plasma 
concentration. 
 
Fig. 1. Amount of GEN diffused in vitro (a), or penetrated ex ovo (b) or ex vivo (c). 
3.2. ATR-FTIR spectroscopy 
The penetration profile of GEN within the different layers of the SC was established with a 
combination of tape stripping and ATR-FTIR spectroscopy. The most characteristic peaks in 
the ATR-FTIR spectrum of GEN were assigned to the C1 = C2 stretch at 1652 cm−1, and the 
C = O stretch, O7-H22 bend, and ring A C-C stretch at 1518 cm−1 (Fig. 2) [19]. 
Table 1 presents the relative absorbances in the SC layers at 1652 cm−1 and 1518 cm−1, 
which correspond to the amounts of GEN that penetrated into the SC after conventional and 
EP treatments (Fig. 3). The drug delivery and the onset time for transport depend on the 
electrical parameters of the pulses and the physicochemical properties of the drug [3]. It was 
found that EP treatment at 700 V for 1 min EP treatment did not enhance the GEN 
transdermal delivery relative to the conventional treatment. This may be explained by the high 
viscosity of the drug carrier, which decreases the efficacy of EP on the skin [29]. Slightly 
deeper GEN penetration was ensured by EP treatment at 900 V for 1 min, but the total amount 
of GEN did not exceed that for conventional treatment with LLC-GEN. However, EP 
treatment at 700 V for 2 min resulted in a deeper penetration of a 2-fold amount of the drug 
than without EP treatment (revealed at both characteristic bonds of GEN). The best 
penetration profile of GEN was obtained on EP treatment at 900 V for 2 min, when the total 
amount of the drug was 3-fold greater as compared with conventional treatment at both 
assigned bonds (p < 0.001*** and p < 0.05*), but the GEN distribution was not consistent. 
The presence of GEN was not seen in the 5th and 6th tape strips, whereas the drug appeared 
again in the 7th strips. This phenomenon could be explained by the electrical breakdown of 
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the SC layers. Furthermore the amount of drug that penetrated increased with increasing 
voltage of the pulses [30, 31]. 
 
Fig. 2. ATR-FTIR spectra of pure GEN (a), Cremophor RH 40 (b), isopropyl myristate (c), 
LLC-GEN composition (d) and non-treated SC (e). 
Table 1. Intensities of GEN in the different layers of the treated SC (average value ± SD, 
n = 3) (CT = conventional treatment). 
Treated with 
LLC-GEN (CT, 
2 min) 
Treated with 
LLC-GEN + EP 
(700 V, 1 min) 
Treated with 
LLC-GEN + EP 
(900 V, 1 min) 
Treated with 
LLC-GEN + EP 
(700 V, 2 min) 
Treated with 
LLC-GEN + EP 
(900 V, 2 min) 
No. 
of 
tape 
strips 
Absorbance at Absorbance at Absorbance at Absorbance at Absorbance at 
1652 
cm−1 
GEN 
1518 
cm−1 
GEN 
1652 
cm−1 
GEN 
1518 
cm−1 
GEN 
1652 
cm−1 
GEN 
1518 
cm−1 
GEN 
1652 
cm−1 
GEN 
1518 
cm−1 
GEN 
1652 
cm−1 
GEN 
1518 
cm−1 
GEN 
1 
0.06 ± 
0.03 
0.05 ± 
0.02 
0.05 ± 
0.05 
0.04 ± 
0.04 
0.04 ± 
0.01 
0.03 ± 
0.00 
0.15 ± 
0.02 
0.12 ± 
0.02 
0.22 ± 
0.10 
0.18 ± 
0.08 
2 
0.03 ± 
0.01 
0.03 ± 
0.01 
0.02 ± 
0.02 
0.02 ± 
0.01 
0.01 ± 
0.01 
0.01 ± 
0.01 
0.04 ± 
0.02 
0.04 ± 
0.02 
0.08 ± 
0.06 
0.07 ± 
0.05 
3 
0.03 ± 
0.02 
0.02 ± 
0.01 - - 
0.03 ± 
0.00 
0,03 ± 
0.00 
0.06 ± 
0.00 
0.05 ± 
0.00 
0.06 ± 
0.00 
0.05 ± 
0.00 
4 - - - - 
0.03 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.02 ± 
0.00 
0.03 ± 
0.01 
0.03 ± 
0.01 
5 - - - - - - 
0.01 ± 
0.00 
0.01 ± 
0.00 - - 
6 - - - - - - - - - - 
7 - - - - - - - - 
0.02 ± 
0.02 
0.02 ± 
0.01 
8 - - - - - - - - - - 
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 Fig. 3. Total intensities of GEN at 1652 cm−1 and at 1518 cm−1. Conventional treatment (CT) 
was used as a control. p < 0.001*** and p < 0.05* vs. EP-treated group. 
3.2. Raman spectroscopy 
The deeper skin penetration of LLC-GEN containing the lipophilic ingredients CRH40 and 
IPM was studied in Raman scattering experiments. Raman chemical mapping was employed 
to confirm the localization of GEN at various depths of the skin specimens. Since ATR-FTIR 
demonstrated that EP treatment at 900 V ensured deeper penetration than that at 700 V, EP 
treatments at 900 V for 1 and 2 min were chosen for comparison with conventional treatment 
by Raman spectroscopy. 
Figure 4 depicts the experimental Raman spectra of pure CRH40, IPM and GEN in the 
wavenumber range 2000-200 cm−1. As model solution, GEN was dissolved in CRH40 and 
IPM containing LLC (GEN content 3 wt.%) to observe the physical state of GEN. Six 
common characteristic ranges can be seen in the spectra of CRH40 and IPM, with peaks 
centred at 1733, ∼1442-1437, 1300, 1063 and 843-823 cm−1, and the spectra of CRH40, IPM 
and the LLC-GEN composition are very similar. Table 2 lists the Raman bands of the 
components and the LLC-GEN composition. The lipid components used in this study have 
similar chemical structures and therefore similar Raman bands. The Raman spectrum of the 
LLC-GEN is basically the sum of the individual spectra, with minor shifts at around 1440 and 
1079 cm−1 (Fig. 4(c)), indicating that the CH2-CH3 bonds of the LLC ingredients were 
affected by the interaction. Only a few Raman peaks of GEN were observed in the spectrum 
of LLC-GEN, at around 1617, 1062, 991, 887 and 789 cm−1. For GEN, two characteristic 
peaks, centred at 1617 and 789 cm−1, were assigned to the vibration of the C = C bond in ring 
B and the C-C-C, C-C and C = O bonds in ring C of the isoflavonoid molecule. These bands, 
free from interference from LLC ingredient bands, were chosen to confirm the localization of 
GEN in the skin specimen. 
Raman spectra were acquired from skin treated with LLC-GEN and from non-treated 
intact ex vivo skin (Fig. 5), both perpendicular to the SC at equivalent depth (1000 µm). In the 
Raman spectrum of the treated skin, characteristic peaks of GEN and the LLC ingredients 
were observed at around 1670-1650 and 1470-1410 cm−1, respectively. The band of interest 
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Fig. 4. Experimental Raman spectra of Cremophor RH 40 (a), isopropyl myristate (b), LLC-
GEN composition (c) and pure GEN (d). 
Table 2. Observed Raman peaks and peak assignments of individual components and 
LLC-GEN (str = stretching, def = deformation, tw = twisting). 
Assignment Cremophor RH 40 
Isopropyl 
myristate LLC-GEN GEN 
str C = O (ester) 1734 1733 1733 -
str C = C (ring A) - - 1648 1648
str C = C (ring B) - - 1617 1617
def CH2-CH3 1442 1437 1440 -
str C = C - - - 1366
 - - - 1319
def CH2 and tw 
CH3 
1300 1300 1300 -
str C-C 1139 - - -
  1079 1076 -
str O-C 1063 1062 1063 1062
str C = C and C-
C-C (ring A) 
- - 991 991
str C = C (ring A) 
and C-C-C (ring 
C) 
- - 887 887
str C-CH 
(aromatic ring) 
843 - - -
 - 823 824 -
str C-C-C (C 
ring), str C = O 
- - 789 791
str C-C-C and C = 
C (ring A) 
- 601 596 596
str C-C-C (rings A 
and C) 
- - - 566
centred at 1440 cm−1 was assigned to the vibration of the amide functional group due to C = O 
stretching and –CH2, -CH3 bending of the skin lipid constituents. The C = C stretching 
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observed at 1617 cm−1 arose predominantly from the GEN isoflavonoid. The chemical 
mapping therefore confirmed the presence of the characteristic GEN band at around 1617 
cm−1. This peak is close to the vibrations of the native skin components. The skin component 
peaks at 1608 and 1453 cm−1 are well known to be associated with the C = C vibration of 
phenylalanine, the CH2 scissoring of lipids and the CH2, CH3 deformation of proteins in the 
native skin. 
 
Fig. 5. Raman spectra of GEN-treated skin (900 V, 2 min, 1000 µm depth) (a), non-treated skin 
specimen as control (1000 µm depth) (b), pure GEN (c) and GEN-free LLC composition (d) in 
the range 1900-1350 cm−1. 
Figure 6 displays qualitative distribution maps of the LLC components and GEN in animal 
skin specimens after different EP protocols, at 10-fold magnification. It was of interest to 
determine whether GEN diffusion is limited to the SC or to the epidermis or dermis. As 
discussed in the Materials and methods section, as the skin specimens were planar, there was 
no need for the z-axis and adjustment of the depth values. 1300 µm deep sections of the skin 
specimen were investigated, from corresponding top to bottom to the SC → epidermis → 
dermis. In order to confirm GEN diffusion, the chemical maps were resolved. The 
characteristic bands obtained for GEN at around 1617 cm−1 were used to visualize the spatial 
distribution of GEN from the Raman chemical mapping. The resolution of the chemical map 
and hence the identification of the ingredients present were achieved by using a multivariate 
curve resolution – alternating least squares chemometric method. This method furnishes the 
response profiles of different components in complex samples, and provides information 
about the composition. 
The presence of bands due to GEN and the LLC components in the upper layer of the skin 
(0-1000 µm) clearly indicates a good distribution following conventional treatment of the 
LLC-GEN composition (Fig. 6(a)). After the 900 V process for 1 min, GEN was accumulated 
in the middle section of the dermis (Fig. 6(b)). The penetration of GEN into the dermis was 
slowed by the dermis a being dense network of collagen fibres. The GEN and LLC 
component contents of the skin specimen (to a depth of 1300 µm) were relatively low after 
the 900 V EP process for 2 min (Fig. 6(c)), indicating that the GEN penetrated into the deep 
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layer of the dermis. Although the difference between the EP processes for 1 and 2 min may 
seem minor, the slower diffusion of GEN may be presumed because of the enrichment of the 
LLC components (as vehicles of GEN) in the 1000-1300 µm deep section. In the absence of 
the EP process, the epidermal and upper dermal regions serve as a tight barrier, impeding 
deep GEN delivery. Thus, slow diffusion of the GEN took place. 
 
Fig. 6. Qualitative Raman maps of GEN distribution in animal skin specimens following 
different EP protocols (at 10-fold magnification). Conventionally treated skin as control (a), 
skin treated with EP at 900 V for 1 min (b) and skin treated with EP at 900 V for 2 min (c). 
Image: LLC-GEN composition, CRH + IPM: Cremophor RH 40 + isopropyl myristate, GEN: 
Genistein. Colour coding of content: red>yellow>green>blue. 
4. Conclusions 
In summary, the results of this study have demonstrated that our newly developed LLC 
formulation is a suitable carrier for the poor water soluble GEN. The penetration through the 
skin was ensured already by LLC-GEN alone application. However the combination of LLC 
nanocarrier system with EP was resulted rapid and more effective transdermal drug transport 
than alone LLC-GEN formulation. The synergistic effect of EP was verified by both the ATR-
FTIR and the Raman spectroscopy. It could be concluded from our study that combination of 
LLC an EP process is very promising, but the optimization of drug penetration is necessary. 
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